
Which GLP-1 Is Best for Weight Loss? Wegovy, Zepbound, the New Pills and More (Nov 2026)
Zepbound beat Wegovy in the only head-to-head trial. Compare every FDA-approved GLP-1 for weight: trial results, pills, side effects and Nov 2026 prices.
Written by Diana Gangan. Updated November 10, 2026.
If you only care about the most weight lost, the answer to which GLP-1 is best for weight loss is Zepbound (tirzepatide): in SURMOUNT-5, the only head-to-head trial, it beat Wegovy (semaglutide 2.4 mg), with average losses of 20.2% against 13.7% of body weight over 72 weeks. A GLP-1 drug copies a gut hormone that reduces appetite; tirzepatide also acts on a second hormone, GIP. But "best" is not only about the biggest number. As of November 2026 there are five FDA-approved GLP-1 options for weight: the Wegovy injection, Wegovy HD 7.2 mg, the Wegovy pill, Zepbound and the Foundayo pill, plus generic liraglutide. Ozempic, Rybelsus and the new Ozempic tablets are diabetes drugs and are not approved for weight loss. This guide compares them using trial and label data.
Which GLP-1 Is Best for Weight Loss: The Short Answer
- 1Most weight loss in a direct comparison: Zepbound beat Wegovy 2.4 mg in SURMOUNT-5 (20.2% vs 13.7%).
- 2Highest semaglutide option: Wegovy HD 7.2 mg (20.7% in STEP UP, efficacy estimand), but it has never been tested against Zepbound.
- 3Best pill: the Wegovy pill lost more weight in its trial; Foundayo is easier to take because it has no food rules. They have not been compared directly.
- 4Proven heart benefit: Wegovy is the only weight-loss GLP-1 labelled to cut heart attack and stroke risk.
- 5Sleep apnea: Zepbound is the only one approved for obstructive sleep apnea.
- 6Not weight-loss drugs: Ozempic, Rybelsus and Ozempic tablets are approved for type 2 diabetes only.
Which GLP-1 Drugs Are FDA-Approved for Weight Loss in 2026?
Wegovy (semaglutide) is a weekly injection approved for chronic weight management in adults and children 12 and older, for reducing the risk of heart attack, stroke and cardiovascular death in adults with heart disease and overweight, and, under accelerated approval, for a form of fatty liver disease called MASH. Wegovy HD, a 7.2 mg weekly dose, was approved on March 19, 2026, for adults who have tolerated 2.4 mg for at least four weeks. The Wegovy pill, a 25 mg once-daily tablet of semaglutide, was approved on December 22, 2025, and launched in the US on January 5, 2026. See Wegovy pill vs injection.
Zepbound (tirzepatide) is a weekly injection approved for weight in November 2023 and for obstructive sleep apnea in adults with obesity in December 2024. Foundayo (orforglipron), approved on April 1, 2026, is a once-daily pill that can be taken with or without food. Liraglutide 3 mg is a daily injection; Novo Nordisk is discontinuing its Saxenda brand in the US, but a generic version from Teva has been available since August 2025.
FDA-approved GLP-1 weight-loss options, November 2026
Wegovy
Semaglutide 2.4 mg
Weekly injection
Weight (age 12+), heart risk reduction, MASH
$349/month (NovoCare)
Wegovy HD
Semaglutide 7.2 mg
Weekly injection
Weight (adults, after 4+ weeks on 2.4 mg)
$399/month (NovoCare)
Wegovy pill
Oral semaglutide 25 mg
Daily tablet
Weight, heart risk reduction
$149 to $299/month by dose (NovoCare)
Zepbound
Tirzepatide
Weekly injection (pen or vial)
Weight, obstructive sleep apnea
$299 to $449/month by dose with timely refills (LillyDirect)
Foundayo
Orforglipron
Daily tablet
Weight
$149 to $299/month by dose (LillyDirect)
Saxenda / generic
Liraglutide 3 mg
Daily injection
Weight; Saxenda brand leaving the US
Not listed here
Which GLP-1 Causes the Most Weight Loss?
Each drug was tested against a placebo in its own trial. Those trials enrolled different people for different lengths of time, so comparing their numbers side by side is only a rough guide; SURMOUNT-5 is the only trial that compared two drugs directly. The "treatment policy" estimand counts everyone who started; the "efficacy" estimand assumes people stayed on the drug, so its numbers are bigger. The table names which one each figure uses where our source states it. More detail on realistic results with semaglutide is in how much weight you can lose on Wegovy.
Average body-weight change in pivotal trials (not head-to-head unless stated)
STEP 1
1,961
68
Wegovy 2.4 mg
-14.9% vs -2.4%
Treatment policy
STEP UP
1,407
72
Wegovy HD 7.2 mg (vs 2.4 mg)
-20.7% (2.4 mg: -17.5%) vs -2.4%
Efficacy
STEP UP
1,407
72
Wegovy HD 7.2 mg (vs 2.4 mg)
-18.7% (2.4 mg: -15.6%) vs -3.9%
Treatment policy
OASIS 4
307
64
Wegovy pill 25 mg
-13.6% (-16.6% if adherent)
Treatment policy (efficacy in brackets)
SURMOUNT-1
2,539
72
Zepbound 5 / 10 / 15 mg
-15.0% / -19.5% / -20.9% vs -3.1%
Not stated in summary
ATTAIN-1
3,127
72
Orforglipron 36 mg trial arm
-12.4% vs -0.9%
Efficacy
ATTAIN-1
3,127
72
Orforglipron 36 mg trial arm
-11.2% vs -2.1%
Treatment regimen
SURMOUNT-5 (head-to-head)
751
72
Tirzepatide vs semaglutide, max tolerated dose
-20.2% vs -13.7%
Not stated in summary
On these numbers, Zepbound at 10 or 15 mg and Wegovy HD 7.2 mg sit at the top, at around 20%, followed by Wegovy 2.4 mg and the Wegovy pill, then Foundayo. ATTAIN-1 figures are from a 36 mg trial arm, which differs from the 17.2 mg top marketed strength. A 2026 network meta-analysis in the journal Obesity, which pooled 15 trials and was described by the University of Georgia, reached a similar ranking: tirzepatide above 20%, semaglutide around 15% and liraglutide around 8%.
Wegovy vs Zepbound vs Foundayo: What Did SURMOUNT-5 Show?
SURMOUNT-5 randomly assigned 751 adults with obesity but without diabetes to tirzepatide (the drug in Zepbound) or semaglutide (the drug in Wegovy) for 72 weeks, each at the highest dose the person tolerated: 10 or 15 mg for tirzepatide and 1.7 or 2.4 mg for semaglutide. Average loss was 20.2% (22.8 kg) against 13.7% (15.0 kg). About 48.4% on tirzepatide lost at least a fifth of their weight, against 27.3%. The trial was open-label (participants knew their drug) and it was funded by Eli Lilly, which makes Zepbound. It did not include Wegovy HD or either pill. Our full comparison is in Zepbound vs Wegovy.
Is Wegovy HD 7.2 mg the Strongest Weight Loss Injection?
Not proven. In STEP UP, 7.2 mg semaglutide produced 20.7% average weight loss against 17.5% with 2.4 mg (efficacy estimand), or 18.7% against 15.6% counting everyone who started. The Medical Letter noted in 2026 that there is no head-to-head trial of 7.2 mg against tirzepatide. It is only for adults who have tolerated 2.4 mg for at least four weeks. The higher dose brought more side effects, including dysesthesia, an unusual skin sensation such as tingling or burning, in 22% of people against 6% on 2.4 mg. Details are in our guide to Wegovy HD 7.2 mg.
Which GLP-1 Pill Is Best for Weight Loss: Wegovy Pill or Foundayo?
The two pills have not been compared directly. In its own trial, the Wegovy pill produced 13.6% average weight loss over 64 weeks counting everyone who started, or 16.6% for people who kept taking it. Foundayo's 36 mg trial arm produced 11.2% to 12.4% over 72 weeks. On cross-trial numbers the Wegovy pill looks somewhat stronger, and it has a heart risk reduction claim.
Foundayo is simpler to take. The Wegovy pill label says to swallow it on an empty stomach with no more than 4 ounces of water and wait 30 minutes before eating, drinking or taking other oral medicines; it is started at 1.5 mg and increased every 30 days through 4 mg and 9 mg to 25 mg. Foundayo can be taken with or without food. The Wegovy pill also raised levels of thyroid hormone by about 33% in people taking levothyroxine, so thyroid doses may need checking. For tolerability, see Wegovy pill side effects.
Which GLP-1 Has the Fewest Side Effects?
All GLP-1 drugs commonly cause nausea, vomiting, diarrhea and constipation, mostly during dose increases. Zepbound's nausea rates were 25% to 29% across doses against 8% with placebo, lower than Wegovy 2.4 mg's 44% against 16%. Fewer people stopped Zepbound for side effects (4.8% to 6.7%) than Saxenda (9.8%). The 36 mg orforglipron arm had the highest stopping rate in the table below. All carry a boxed thyroid C-cell tumor warning and are not for people with a personal or family history of medullary thyroid cancer or MEN 2.
Side effects and stopping rates on the label or in trials
Wegovy 2.4 mg
44% vs 16%
6.8% vs 3.2%
Wegovy HD 7.2 mg
39% (2.4 mg: 35%) vs 13%
5% (2.4 mg: 5%) vs 2%
Wegovy pill 25 mg
46.6% vs 18.6% (company release)
6.9% vs 5.9%
Zepbound 5 / 10 / 15 mg
25% / 29% / 28% vs 8%
4.8% / 6.3% / 6.7% vs 3.4%
Orforglipron 36 mg trial arm
33.7% vs 10.4%
10.3% vs 2.7%
Saxenda 3 mg
39.3% vs 13.8%
9.8% vs 4.3%
Can You Use Ozempic or Rybelsus for Weight Loss?
Not as approved uses. Ozempic (weekly semaglutide injection) and Rybelsus (daily semaglutide tablet) are approved for type 2 diabetes, not for weight management. In the US, Rybelsus has been reformulated as Ozempic tablets in 1.5, 4 and 9 mg strengths, launched on May 4, 2026; these are also diabetes-only. If weight loss is the goal, the Wegovy injection or Wegovy pill is the version approved for it. See Wegovy vs Ozempic. We also do not recommend compounded or "microdosed" versions of any GLP-1; the evidence is covered in our article on microdosing GLP-1 drugs.
Is Saxenda Being Discontinued?
Yes, in the US. Novo Nordisk says it is discontinuing Saxenda, with last shipments to wholesalers in late January 2027, and that this is a portfolio decision, not the result of any safety or quality concern. Teva's generic liraglutide 3 mg launched around August 28, 2025. If you use Saxenda, ask your doctor about the generic or another option.
What Is the Cheapest GLP-1 for Weight Loss Without Insurance?
Manufacturer self-pay pages checked on November 10, 2026, show the pills start cheapest. The Wegovy pill costs $149 a month at 1.5 mg, $199 at 4 mg and $299 at 9 or 25 mg through NovoCare. Foundayo costs $149 at 0.8 and 2.5 mg, $199 at 5.5 mg (temporary through December 31, 2026) and $299 at higher doses through LillyDirect. The Wegovy injection is $349 a month at any dose, with $199 for the first two fills of the 0.25 or 0.5 mg dose through December 31, 2026, and Wegovy HD is $399. Zepbound costs $299 at 2.5 mg, $399 at 5 mg and $449 at 7.5 to 15 mg if refilled within 45 days, otherwise $499 or $699. Wegovy's $1,349.02 list price falls to $675 on January 1, 2027.
With commercial insurance that covers Wegovy, the NovoCare savings offer can bring the copay to as little as $25 (maximum savings $100); it excludes people on government insurance. Since July 1, 2026, the Medicare GLP-1 Bridge offers Wegovy (injection or tablet), Zepbound KwikPen and Foundayo for $50 a month to people with a BMI of 35 or higher, a BMI of 30 or higher with certain heart failure, uncontrolled high blood pressure or chronic kidney disease, or a BMI of 27 or higher with prediabetes or a prior heart attack, stroke or peripheral artery disease. It excludes people with type 2 diabetes, sleep apnea or MASH, whose Part D plan may cover a GLP-1 instead. Private coverage is explained in does insurance cover Wegovy.
Which GLP-1 Fits Which Person?
- 1Maximum weight loss and you are happy with a weekly shot: Zepbound has the only head-to-head win.
- 2Heart disease with overweight or obesity: Wegovy injection or pill, the only options labelled to reduce heart attack and stroke risk, based on the SELECT trial.
- 3Obstructive sleep apnea: Zepbound, the only GLP-1 approved for it.
- 4MASH (fatty liver with inflammation): Wegovy injection, under accelerated approval; see Wegovy for fatty liver.
- 5Dislike needles: the Wegovy pill for more weight loss, or Foundayo if empty-stomach rules would be hard to follow.
- 6Already on Wegovy 2.4 mg and plateaued: Wegovy HD 7.2 mg is an option after at least four weeks on 2.4 mg.
- 7Tight budget: the lowest pill doses start at $149 a month; Medicare patients should check the $50 Bridge.
Is Retatrutide Better, and When Could It Be Approved?
Retatrutide is an investigational Eli Lilly drug acting on three hormone receptors. In topline results from the 80-week TRIUMPH-1 trial, the highest dose produced 28.3% average weight loss (efficacy estimand); these results have not yet been peer-reviewed. Lilly plans to submit it to the FDA in the first quarter of 2027 and says it is legally available only to participants in its clinical trials. We do not give dosing for it.
When to Talk to Your Doctor
- 1Severe or persistent stomach pain, (possible pancreatitis or gallbladder disease)
- 2Vomiting or diarrhea that stops you keeping fluids down
- 3A lump or swelling in the neck, trouble swallowing or a hoarse voice
- 4Signs of an allergic reaction, such as facial swelling or trouble breathing
- 5Low blood sugar symptoms if you also take insulin or a sulfonylurea
- 6Pregnancy or plans for pregnancy
Questions to Ask Your Doctor Before Choosing a GLP-1
- 1Which approved options does my insurance or Medicare cover, and what will I pay each month?
- 2Do my other conditions, such as heart disease, sleep apnea or fatty liver, favour one drug?
- 3Would a pill or a weekly injection fit my routine better?
- 4How will we manage nausea while the dose goes up?
- 5Do any of my medicines, such as levothyroxine or insulin, need adjusting?
The Bottom Line
Zepbound has the strongest evidence for the most weight loss, because it beat Wegovy 2.4 mg in the only head-to-head trial. Wegovy HD 7.2 mg reaches similar numbers in its own trial but has not been compared directly. The pills offer needle-free options with somewhat less weight loss. Retatrutide is still investigational. The best GLP-1 for weight loss in 2026 is the approved one that suits your health, your routine and your budget.
FAQ
In SURMOUNT-5, the only head-to-head trial, Zepbound produced 20.2% average weight loss against 13.7% with Wegovy 2.4 mg over 72 weeks. Wegovy HD 7.2 mg was not part of that trial.
Among approved drugs, Zepbound at 10 or 15 mg and Wegovy HD 7.2 mg reach about 20% average weight loss in their own trials. Only Zepbound has beaten another GLP-1 in a direct comparison.
The Wegovy pill lost more weight in its trial (13.6% to 16.6%) than Foundayo's 36 mg trial arm (11.2% to 12.4%), but they have not been compared directly. Foundayo has no food or water rules.
They are approved only for type 2 diabetes. Wegovy, which contains the same drug, is the version approved for weight management.
Yes, in the US, with last shipments in late January 2027. Novo Nordisk says it is not a safety issue. Generic liraglutide 3 mg remains available.
As of November 10, 2026, the lowest manufacturer self-pay prices are $149 a month for the starting doses of the Wegovy pill and Foundayo. Medicare patients who qualify for the GLP-1 Bridge pay $50 a month.
Sources
- 1Wegovy (semaglutide) injection prescribing information, DailyMed, 2026
- 2FDA approves fourth product under National Priority Voucher Program, higher dose semaglutide, FDA, 2026
- 3Wegovy HD prescribing information, FDA, 2026
- 4Wegovy tablets approval letter, FDA, 2025
- 5Wegovy (semaglutide) injection and tablets prescribing information, FDA, 2026
- 6Zepbound (tirzepatide) prescribing information, DailyMed, 2026
- 7Saxenda (liraglutide) prescribing information, FDA
- 8Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity, New England Journal of Medicine, 2021
- 9Lincoff AM et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT), New England Journal of Medicine, 2023
- 10Tirzepatide once weekly for the treatment of obesity: SURMOUNT-1, American College of Cardiology, 2022
- 11Higher dose of Wegovy provided average weight loss of 21% (STEP UP), BioSpace, 2025
- 12SURMOUNT-5: tirzepatide (Zepbound) proves benefit over semaglutide (Wegovy) for obesity, HCPLive, 2025
- 13FDA approves semaglutide (Wegovy) pill as first oral GLP-1 for weight loss, HCPLive, 2025
- 14Lilly's oral GLP-1, orforglipron, demonstrated meaningful weight loss (ATTAIN-1), Eli Lilly, 2025
- 15FDA approves Lilly's Foundayo (orforglipron), Eli Lilly, 2026
- 16Lilly's triple agonist, retatrutide, delivered powerful weight loss (TRIUMPH-1), Eli Lilly, 2026
- 17Saxenda product information and US discontinuation, Novo Nordisk, 2026
- 18FDA approves generic liraglutide injection for weight loss, Pharmacy Times, 2025
- 19Ozempic approval history, Drugs.com, 2026
- 20Medicare GLP-1 Bridge: GLP-1 drugs for $50 a month, Medicare.gov, 2026
- 21Wegovy cost and savings, NovoCare (Novo Nordisk), accessed November 2026
- 22Zepbound self-pay pricing, LillyDirect (Eli Lilly), accessed November 2026
- 23Foundayo self-pay pricing, LillyDirect (Eli Lilly), accessed November 2026
- 24Novo Nordisk announces significant reduction in US list price for Wegovy, BioSpace, 2026
This article summarizes published research and prescribing information for general information and is not medical advice. Most trials cited were funded by the drugs' manufacturers, Novo Nordisk and Eli Lilly; SURMOUNT-5 was funded by Eli Lilly.

Diana Gangan
Author
Comments (0)
Be the first to comment on this article.




